BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board



    Toronto Stock Exchange Symbol: MS

    EDMONTON, April 21 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal
phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with
secondary progressive MS has completed a safety analysis and recommended that
the trial continue as per the protocol.
    This was the final scheduled review by the DSMB prior to the completion
of MAESTRO-01. The purpose of the DSMB is to provide objective, independent
safety monitoring of the trial. Results from MAESTRO-01 are expected in the
second half of this year.

    
    About MAESTRO-01
    ----------------
    

    MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial
designed to evaluate the safety and efficacy of dirucotide in patients with
secondary progressive MS. The study is being conducted at 47 sites across
Canada and nine countries in Europe and includes 611 patients being
administered either dirucotide or placebo intravenously every six months for a
period of two years. The primary clinical endpoint for the trial is defined as
a statistically and clinically significant increase in the time to progression
of the disease, as measured by the Expanded Disability Status Scale (EDSS), in
patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all
MS patients are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression
in patients with other HLA-DR types will be assessed separately as an
exploratory arm of the same study.

    
    About BioMS Medical Corp.
    -------------------------
    

    BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, dirucotide, is for the treatment of multiple sclerosis and is
being evaluated in two pivotal phase III clinical trials for Secondary
Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company exclusive worldwide
rights to dirucotide in exchange for an $87 million upfront payment, milestone
payments and escalating royalties on sales. For further information please
visit our website at http://www.biomsmedical.com

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that MBP8298 will continue to demonstrate a satisfactory safety
profile in ongoing and future clinical trials; and that BioMS Medical Corp.
will complete the respective clinical trials within the timelines communicated
in this release. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.






For further information:

For further information: Tony Hesby, Ryan Giese, Amanda Stadel, BioMS
Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail:
info@biomsmedical.com, Internet: http://www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:
jsmith@equicomgroup.com

Organization Profile

Medwell Capital Corp.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890